Although the molecular mechanisms behind the competitive effect of NF-κB/p65 and PPARγ are not clear and have to be thoroughly studied, this study provides novel and valuable evidence on the pathology of PAH. The gene discussed is NFKB1; the disease is pulmonary arterial hypertension.